Radiation Therapy News and Research RSS Feed - Radiation Therapy News and Research

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.
Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Shorter course of whole breast radiation therapy better for women with early stage breast cancer

Women who receive a shorter course of whole breast radiation therapy for early stage disease experience less toxicity and improved quality of life compared to those who undergo a longer course of treatment, researchers report from The University of Texas MD Anderson Cancer Center. [More]
Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan receives FDA approval to market 28 additional styles of Natrelle 410 silicone-filled breast implants

Allergan, plc. today announced that the company has received approval from the U.S. Food and Drug Administration to market 28 additional styles of Natrelle 410 silicone-filled breast implants, giving surgeons and patients more options to achieve desired outcomes. [More]
EORTC study: Irradiation of regional nodes in breast cancer patients has marginal effect on overall survival

EORTC study: Irradiation of regional nodes in breast cancer patients has marginal effect on overall survival

At a median follow-up of 10.9 years, an EORTC study has shown that irradiation of regional nodes in patients with stage I, II, or III breast cancer has a marginal effect on overall survival, the primary endpoint (at 10 years, overall survival was 82.3 % for regional irradiation versus 80.7% for no regional irradiation, (HR=0.87 (95%CI: 0.76, 1.00), p=0.06). [More]
Research: Failure to control early, localized prostate cancer leads to poor clinical outcome

Research: Failure to control early, localized prostate cancer leads to poor clinical outcome

Failure to control early, localized prostate cancer results in a poor clinical outcome, according to research published in the International Journal of Radiation Oncology Biology Physics. [More]
Protecting gastrointestinal system during radiation or chemotherapy allows patients to tolerate cancer treatments

Protecting gastrointestinal system during radiation or chemotherapy allows patients to tolerate cancer treatments

The stem cells in our gut divide so fast that they create a completely new population of epithelial cells every week. But this quick division is also why radiation and chemotherapy wreak havoc on the gastrointestinal systems of cancer patients - such therapies target rapidly dividing cells. [More]
Endocrine Society recommends removal of tumor as first-line treatment for endogenous Cushing's syndrome

Endocrine Society recommends removal of tumor as first-line treatment for endogenous Cushing's syndrome

The Endocrine Society today issued a Clinical Practice Guideline (CPG) on strategies for treating Cushing's syndrome, a condition caused by overexposure to the hormone cortisol. [More]
Prostate cancer patients more likely to receive medical care matched to level of risk

Prostate cancer patients more likely to receive medical care matched to level of risk

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at UC San Francisco. [More]
Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. [More]
ASTRO concerned about proposed Medicare physician payment cuts to radiation therapy

ASTRO concerned about proposed Medicare physician payment cuts to radiation therapy

The American Society for Radiation Oncology is concerned about proposed additional payment cuts to radiation therapy detailed in the Centers for Medicare and Medicaid Services' proposed Medicare Physician Fee Schedule (MPFS), released July 8, 2015, which will take effect on January 1, 2016. [More]
Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy. [More]
Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose offers survival benefit for men with medium- and high-risk prostate cancer

Increased radiation dose is associated with higher survival rates in men with medium- and high-risk prostate cancer, but not men with low-risk prostate cancer, according to a new study from Penn Medicine published this week in JAMA Oncology. Already-high survival rates for men with low-risk prostate cancer were unaffected by higher radiation dosages compared to lower radiation dosages. [More]
Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray announces presentation of CyberKnife System data at AAPM annual meeting

Accuray Incorporated announced today that studies on the clinical use of the CyberKnife System, the only robotic SBRT system capable of tracking and automatically correcting for target motion, continue to demonstrate the benefits of its precise, innovative treatment delivery techniques. [More]
Clinical data on TomoTherapy System presented at AAPM 2015

Clinical data on TomoTherapy System presented at AAPM 2015

Accuray Incorporated announced today that studies on the clinical use of the TomoTherapy System continue to demonstrate its mainstream use and the benefits of its gold-standard treatment planning and delivery capabilities. More than 30 studies were presented during poster or oral sessions at the 57th Annual Meeting of the American Association of Physicists in Medicine held in Anaheim, California July 12 – July 16, 2015. [More]
Single molecule appears to be central regulator driving cancer metastasis

Single molecule appears to be central regulator driving cancer metastasis

Cancer is a disease of cell growth, but most tumors only become lethal once they metastasize or spread from their first location to sites throughout the body. For the first time, researchers at Thomas Jefferson University in Philadelphia report a single molecule that appears to be the central regulator driving metastasis in prostate cancer. [More]
Southern Ocean Medical Center Auxiliaries pledge $2.5 million to support purchase of TrueBeam linear accelerator

Southern Ocean Medical Center Auxiliaries pledge $2.5 million to support purchase of TrueBeam linear accelerator

The Auxiliaries at Southern Ocean Medical Center recently announced their pledge to raise $2.5 million that will support the purchase of a TrueBeam linear accelerator, the most advanced radiation therapy technology, for the hospital. The announcement was made at Southern Ocean Medical Center Foundation's Signature Social fundraising event on July 10 at Bonnet Island Estate. [More]
Accuray, RaySearch sign long-term collaboration agreement for RayCare oncology information system

Accuray, RaySearch sign long-term collaboration agreement for RayCare oncology information system

Accuray Incorporated and RaySearch Laboratories AB (publ) announced today they have signed a long-term collaboration agreement which will allow Accuray to co-market and offer the RayCare oncology information system (OIS) which is currently in development at RaySearch. [More]
OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex Pharmaceuticals, Inc. announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee (IDMC). This decision was based upon completion of the second and final planned interim futility analysis. [More]
Three European medical centers planning upgrades to Elekta's stereotactic radiosurgery system for the brain

Three European medical centers planning upgrades to Elekta's stereotactic radiosurgery system for the brain

Three foremost medical centers in the United Kingdom and Germany have ordered and are now planning upgrades to Elekta's latest generation stereotactic radiosurgery system for the brain, Leksell Gamma Knife Icon, to provide the most advanced brain radiosurgery treatments for their patients. [More]
KF-SYSCC creates paperless, filmless clinical process in radiation oncology to enhance patient safety

KF-SYSCC creates paperless, filmless clinical process in radiation oncology to enhance patient safety

The Koo Foundation Sun Yat-Sen Cancer Center has established an entirely paperless and filmless clinical process in radiation oncology, designed to enhance patient safety as well as operational efficiency. Using the ARIA oncology information system from Varian Medical Systems, the clinical team has automated essential tasks, built in safety-checks, and centralized patient information for easier access by staff members. [More]
Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers launch world's first viral therapy clinical trial to attack and kill cancer cells

Canadian researchers have launched the world's first clinical trial of a novel investigational therapy that uses a combination of two viruses to attack and kill cancer cells, and stimulate an anti-cancer immune response. Previous research by this team and others worldwide suggests that this approach could be very powerful, and could have fewer side effects than conventional chemotherapy and radiation, although it will take years to rigorously test through this trial and others. [More]
Advertisement
Advertisement